Target intelligence / Profile preview

Otoferlin (OTOF) (OTOF)

Target
OTOF
Molecular classification
Ferlin family protein, Calcium sensor, Vesicle-trafficking protein
01

Overview

Otoferlin is a large transmembrane protein primarily expressed in the inner hair cells (IHCs) of the cochlea, where it functions as a high-affinity calcium sensor essential for synaptic vesicle exocytosis at the ribbon synapse (UniProt: O88430). It facilitates the rapid and sustained release of neurotransmitters required for the transmission of auditory information to the brain. Mutations in the OTOF gene result in autosomal recessive deafness type 9 (DFNB9), a condition characterized by profound sensorineural hearing loss or auditory neuropathy (NCBI Gene: 9381). Unlike many other forms of genetic deafness, DFNB9 is unique because the cochlear hair cells remain structurally intact for years, providing a window of opportunity for therapeutic intervention. Current clinical-stage treatments utilize gene replacement therapy, specifically dual adeno-associated virus (AAV) vectors, to deliver a functional copy of the OTOF gene directly into the cochlea (ClinicalTrials.gov: NCT05821959, NCT05572515). These therapies aim to restore the protein's function and re-establish hearing sensitivity in pediatric patients.

Other names
Fer-1-like protein 2DFNB9NSRD9Otoferlin
02

Mechanism of action

Gene replacement therapy utilizing dual adeno-associated virus (AAV) vectors to deliver a functional OTOF cDNA to inner hair cells, thereby restoring calcium-triggered glutamate release at the ribbon synapse (PubMed: 31010840).

03

Biological functions

Synaptic vesicle exocytosisCalcium-dependent neurotransmitter releaseAuditory signal transduction
04

Disease associations

Autosomal recessive deafness type 9 (DFNB9)Auditory neuropathy spectrum disorder (ANSD)
05

Safety considerations

AAV-mediated immune responseSurgical risks of intracochlear administrationEfficiency of dual-vector recombinationPotential for off-target gene expression
06

Interacting drugs

DB-OTO

4 more in the full profile.

07

Biomarkers

OTOF gene mutation statusAuditory Brainstem Response (ABR) thresholdsPresence of Otoacoustic Emissions (OAEs)Cochlear Microphonics (CM)

Beyond the preview

Go deeper on Otoferlin (OTOF) (OTOF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otoferlin (OTOF) (OTOF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call